

House Bill 332 (AS PASSED HOUSE AND SENATE)

By: Representatives Parrish of the 158th, Stephens of the 164th, Smith of the 18th, Jasperse of the 11th, and Newton of the 127th

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to provide for certain provisions relating to Schedule I controlled
3 substances, Schedule IV controlled substances, and Schedule V controlled substances; to
4 provide for certain provisions relating to the definition of dangerous drugs; to provide an
5 effective date; to repeal conflicting laws; and for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 **SECTION 1.**

8 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
9 substances, is amended in Code Section 16-13-25, relating to Schedule I controlled
10 substances, by adding a new subparagraph to paragraph (3) to read as follows:

11 "KKKK 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-
12 phenylpropan-2-ol (Zipeprol);"

13 **SECTION 2.**

14 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
15 substances, by revising subparagraphs (A), (B), (C) and (D) of paragraph (4) as follows:

16 "(A) Amineptine;
17 (B) Fenethylline;
18 (B) Reserved;
19 (C) Mesocarb;
20 (D) Methiopropamine;
21 (D)(E) Para-methoxyphenylpiperazine (MeOPP);"

SECTION 3.

23 Said chapter is further amended Code Section 16-13-28, relating to Schedule IV controlled
24 substances, by revising paragraphs (8) and (14) of subsection (a) as follows:

25 "(8) Reserved Daridorexant;"

26 "(14) Fenfluramine Reserved;"

SECTION 4.

28 Said chapter is further amended in Code Section 16-13-29, relating to Schedule V controlled
29 substances, by revising paragraph (1.5) as follows:

30 "(1.5) Reserved Ganaxolone;"

SECTION 5.

32 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
33 defined, by adding new paragraphs to read as follows:

34 "(.0435) Abrocitinib:"

35 "(13.52) Adagrasib:"

36 "(50.2) Anacaulase-bcdb;"

37 "(58.5) Anticoagulant sodium citrate 4 percent solution;"

38 "(60.5) Anti-human globulin;"

39 "(69.25) Axicabtagene ciloleucel;"

40 "(97.105) Betibeglogene autotemcel;"
41 "(97.25) Bexagliflozin;"
42 "(192.8) Ciltacabtagene autoleucel;"
43 "(241.5) DaxibotulinumtoxinA-lanm;"
44 "(256.55) Deucravacitinib;"
45 "(331.045) Eflapegrastim;"
46 "(331.056) Elivaldogene autotemcel;"
47 "(334.45) Epoetin alfa;"
48 "(355.55) Etanercept;"
49 "(381.23) Faricimab-svoa;"
50 "(381.57) Fenfluramine;"
51 "(408.05) Futibatinib;"
52 "(408.45) Gadopiclenol;"
53 "(438.3) Hepatitis C virus (E. coli, recombinant) NS3 helicase antigens and synthetic
54 core peptide;"
55 "(462.5) Hyperpolarized Xe-129;"
56 "(469.03) Inclisiran;"
57 "(513.1) Lecanemab-irmb;"
58 "(513.6) Lenacapavir;"
59 "(531.95) Lutetium (177Lu) vipivotide tetraxetan;"
60 "(540.7) Mavacamten;"
61 "(619.4) Mirvetuximab soravtansine-gynx;"
62 "(619.7) Mitapivat;"
63 "(625.05) Mosunetuzumab-axgb;"
64 "(663.05) Olipudase alfa;"
65 "(663.32) Olutasidenib;"
66 "(663.55) Omidenepag isopropyl;"

67 "(665.65) Oteseconazole;"
68 "(681.32) Pacritinib;"
69 "(832.8) Relatlimab-rmbw;"
70 "(885.3) Spesolimab-sbzo;"
71 "(929.5) Sutimlimab-jome;"
72 "(931.15) Tapinarof;"
73 "(931.205) Taurursodiol;"
74 "(931.4) Tebentafusp-tebn;"
75 "(931.505) Teclistamab-cqyv;"
76 "(931.81) Teplizumab-mzwv;"
77 "(932.5) Terlipressin;"
78 "(967.61) Tirzepatide;"
79 "(967.62) Tisagenlecleucel;"
80 "(973.65) Tralokinumab-ldrm;"
81 "(974.6) Tremelimumab-actl;"
82 "(1018.2) Ublituximab-xiyy;"
83 "(1037.23) von Willebrand factor;"
84 "(1037.27) Vonoprazan;"
85 "(1037.95) Vutrisiran;"

SECTION 6.

87 Said chapter is further amended in Code Section 16-13-71, related to "dangerous drug"
88 defined, by revising paragraphs (386.5), (623.5), and (692.51) of subsection (b) as follows:
89 "(386.5) Filgrastin Filgrastim;"
90 "(623.5) Mometasone – See exceptions;"
91 "(692.51) Pegfilgrastin Pegfilgrastim;"

92

SECTION 7.

93 Said chapter is further amended in Code Section 16-13-71, relating to "dangerous drug"
94 defined, by adding a new paragraph to subsection (c) to read as follows:

95 "(14.23) Mometasone – when used as mometasone furoate in a nasal spray in doses up
96 to 50 mcg per spray;"

97

SECTION 8.

98 This Act shall become effective upon its approval by the Governor or upon its becoming law
99 without such approval.

100

SECTION 9.

101 All laws and parts of laws in conflict with this Act are repealed.